Work

Therapeutic Implications of PTEN Loss in Patients with Cowden Syndrome and Renal Cell Cancer

Year: 2023

Type: article

Abstract: Purpose: Patients with Cowden syndrome (CS) have an increased lifetime risk of developing cancers, particularly breast, uterus, thyroid, colon and renal cell cancer.CS is associated with a germline mutation of PTEN, a gene that plays an important role in carcinogenesis.This review hypothesized that inactivation of PTEN could have dramatic consequences on response of treatments in patients with Cowden Syndrome.Methods: This systematic review has been reported in line with PRISMA and AMSTAR, we investigated to deficit of PTEN and the response to current available treatments for renal cell cancer (RCC).Results: Preclinical studies showed that PTEN loss determinate a growth level of AKT and mTORC1.For this reason, many studies focused on inhibition of mTOR for treatment of patient with Cowden Syndrome's.In addition, preclinical data demonstrated that the loss of PTEN is responsible for the increase in vascular endothelial growth factor (VEGF), to suggest that the VEGF antibody bevacizumab in patients with renal cell carcinoma and CS should be indicated.Conclusion: Cowden syndrome associated renal cell carcinoma patients could benefit from mTOR and anti VEGF therapy, and potentially also by tyrosine kinase inhibitors.Otherwise, immunotherapy the use of would not be recommended.However, confirmatory studies are needed in order to define the role of PTEN as a biomarker of response to treatment.

Source: Surgery Gastroenterology and Oncology

DOI: 10.21614/sgo-588